Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease

Author(s): Matilde Yanez, Dolores Vina

Journal Name: Current Topics in Medicinal Chemistry

Volume 13 , Issue 14 , 2013

Become EABM
Become Reviewer


Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.

Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1692 - 1706]
Pages: 15
DOI: 10.2174/15680266113139990120
Price: $65

Article Metrics

PDF: 44